EUVIMEDEUVIMED entdecken
Systematische Übersicht

Systematic Review: Dexmedetomidine Versus Clonidine in Axillary Brachial Plexus Block — A Clinical Evidence

Neha Jain, Ashok Singh, Afsan Parveen, Manish Shivani, Sumit Bhargava

International Journal of Current Pharmaceutical Review and Research · 30.06.2026 · 18 (06)

DOI: 10.25258/ijcpr.18.6.12 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.06.2026. Verfasst von Neha Jain und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Dexmedetomidine and clonidine are alpha-2 adrenergic agonists frequently used as adjuvants to local anaesthetics in brachial plexus block because they may shorten onset time, improve block quality, and prolong postoperative analgesia. The clinical question addressed in this review is whether dexmedetomidine provides superior efficacy to clonidine when used in axillary brachial plexus block, while maintaining acceptable haemodynamic and safety outcomes. Materials and Methods: A structured clinical evidence synthesis was undertaken using indexed comparative literature on dexmedetomidine versus clonidine as perineural adjuvants in brachial plexus block. Core evidence was drawn from a 2022 meta-analysis of 24 randomized controlled trials 2017 systematic review and metaanalysis of 14 randomized controlled trials. Both reviews compared dexmedetomidine and clonidine as adjuvants to local anaesthetics for upper-limb surgery and analyzed sensory block duration, motor block duration, analgesia duration, onset characteristics, and adverse events.

Result

Across comparative brachial plexus block evidence, dexmedetomidine consistently outperformed clonidine on efficacy endpoints. In the 2022 meta-analysis, dexmedetomidine significantly prolonged sensory block duration by a mean difference of 173.31 minutes, motor block duration by 158.35 minutes, and duration of analgesia by 203.92 minutes compared with clonidine. Dexmedetomidine also hastened onset of sensory block by 1.58 minutes and motor block by 1.46 minutes, and improved the likelihood of higher-grade block quality. The 2017 meta-analysis similarly found that dexmedetomidine increased sensory, motor, and analgesic duration by an estimated ratio of means of about 1.2 each, while also accelerating onset. The 2017 review signaled increased transient bradycardia and postoperative sedation with dexmedetomidine, whereas the 2022 review found no statistically significant difference in hypotension.

Conclusion

The best available evidence suggests that dexmedetomidine is clinically more effective than clonidine as a perineural adjunct in brachial plexus block, with longer sensory and motor blockade, longer postoperative analgesia, and somewhat faster onset.

Zitieren

APA

Jain, N., Singh, A., Parveen, A., Shivani, M., & Bhargava, S. (2026). Systematic Review: Dexmedetomidine Versus Clonidine in Axillary Brachial Plexus Block — A Clinical Evidence. International Journal of Current Pharmaceutical Review and Research, 18(06). https://doi.org/10.25258/ijcpr.18.6.12

Vancouver

Jain N, Singh A, Parveen A, Shivani M, Bhargava S. Systematic Review: Dexmedetomidine Versus Clonidine in Axillary Brachial Plexus Block — A Clinical Evidence. International Journal of Current Pharmaceutical Review and Research. 2026;18(06). doi:10.25258/ijcpr.18.6.12

BibTeX
@article{Jain2026,
  author = {Jain, Neha and Singh, Ashok and Parveen, Afsan and Shivani, Manish and Bhargava, Sumit},
  title = {Systematic Review: Dexmedetomidine Versus Clonidine in Axillary Brachial Plexus Block — A Clinical Evidence},
  journal = {International Journal of Current Pharmaceutical Review and Research},
  year = {2026},
  volume = {18},
  number = {06},
  doi = {10.25258/ijcpr.18.6.12}
}
Kostenlos starten →